In 2010, ibrutinib was demonstrated to have selective toxicity in DLBCL cell lines with chronically active BCR signaling with sub-nanomolar activity (IC50 = 0.5 nM), by preventing the BTK autophosphorylation [40] and in vivo data confirmed its potential [59]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.